Compare IDEXX Laboratories, Inc. (IDXX) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs RLX Technology Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while RLX Technology Inc trades at $1.73 (market cap $2.10B). The key difference: IDEXX Laboratories, Inc. is far larger — about 19.3× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.81% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and RLX Technology Inc for 35 Days on average.
| IDXX | RLX | |
|---|---|---|
Market Cap | $40.43B | $2.10B |
Volume | 692,164 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $2.57 |
52-Week Low | $504.70 | $1.68 |
Typical Hold Time | 46 Days | 35 Days |
Enterprise Value | $41.32B | $832.26M |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
RLX Technology trades at $1.72, down 0.58% and near its 52-week low, with a bearish technical signal from moving averages. Fundamentally, the company shows solid profitability with 21.87% net income margin and attractive valuation metrics including P/E of 15.46 and P/B of 0.91. Recent quarterly earnings have consistently missed expectations, though revenue growth remains positive with 2026 projections showing $4.5B revenue and $985M net income.
The stock presents a value opportunity given discounted valuation, but faces headwinds from earnings misses and bearish technicals. International expansion through European acquisitions provides growth catalysts, though execution risks and margin compression require monitoring. Analyst sentiment remains cautious with 100% hold rating, suggesting limited near-term upside potential despite fundamental strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
